Enteric Dialysis™ Brief Introduction and its Potential for CKD Applications.
This session will brief on the scientific rationale in developing a viable and effective oral probiotic, a beneficial microbial product formulation with several uremic toxin removal capabilities towards human kidney failure applications.
By offering an affordable, readily available and easy-to-administer dietary/nutritional supplement product this probiotic formulation is expected to target renal failure patients worldwide. This human population is in need of an alternative and effective complementary oral product, which will alleviate uremic symptoms and potentially help to slow down or delay the progression of the kidney failure to its final stages requiring dialysis or transplantation.
Efforts in using a probiotic nutritional product formulation have been very successful in unexplored and totally unanticipated veterinary applications in geriatric cats and dogs with moderate to severe kidney failure conditions. The next step is evaluating the probiotic formulation in human Chronic Kidney Failure patients universally. All data collected so far warrants making this step, which will enhance and validate the concept of Enteric Dialysis and bring an easy to use, affordable and minimally invasive product to the CKD patient population worldwide.
When clinically tested and fully validated the unique microbial product formulation may also possess an excellent potential to possibly reduce the duration or frequency of hemo or peritoneal dialysis in the End Stage Renal Disease (ESRD) patients worldwide. General outline of this presentations will be: (A) Current study hypothesis (B) Brief introduction on the microbial eco-flora of the large bowel (C) introduction to Probiotics and currently used probiotic in human clinical applications, (D) Summary of research and development work - In vitro lab studies and with Simulated Human Intestinal Microbial Ecosystem (SHIME) gastrointestinal machine data, (E). 5/6 Nephrectomized Rodent and Minipig studies, (F) Cats and dogs in kidney failure, (G) Human volunteer safety study, (H) on going multi-site pilot scale studies and interim data analysis and, (I) Summary and Conclusions.
The participant speaker of this session will brief on the company's scientific rationale, R&D work, accomplishments and the company's ongoing pilot scale human clinical studies to date both in our laboratory and in several extramural collaborating sites in the U.S. and abroad. Over a decade of efforts have been directed towards developing a viable and effective oral probiotic, a beneficial microbial product formulation with several uremic toxin removal capabilities towards human kidney failure applications.
As will be briefed, these efforts have been very successful in unexplored and totally unanticipated veterinary applications in geriatric cats and dogs with moderate to severe kidney failure conditions. We are now advancing to the next step of evaluating Kibow Biotics - our patented and proprietary probiotic formulation towards human Chronic Kidney Failure patients universally. All the data collected so far warrants making this step, which will enhance and validate the concept of Enteric Dialysis and thus bring our easy to use, economical and affordable product to the CKD patient population worldwide. This human population is in need of an alternative and effective complementary oral product, which will alleviate uremic symptoms and potentially help to slow down or delay the progression of the kidney failure to its final stages requiring dialysis or transplantation. When clinically tested and fully validated in the coming years, our unique microbial product formulation Kibow Biotics may also possess an excellent potential to possibly reduce the duration or frequency of hemo or peritoneal dialysis in the End Stage Renal Disease (ESRD) patients worldwide.
General outline of this presentations will be: (A) Current study hypothesis (B) Brief introduction on the microbial eco-flora of the large bowel (C) introduction to Probiotics and currently used probiotic in human clinical applications, (D) Summary of our R&D work - In vitro lab studies and with Simulated Human Intestinal Microbial Ecosystem (SHIME) gastrointestinal machine data, (E). 5/6 Nephrectomized Rodent and Minipig studies, (F) Cats and dogs in kidney failure, (G) Human volunteer safety study, (H) on going multi-site pilot scale studies and our interim data analysis and, (I) Summary and Conclusions.
